Overview / Abstract: |
Glaucoma is seeing a resurgence in innovative therapeutic developments. The recent approval of two drugs in novel classes for IOP reduction in eyes with ocular hypertension or open-angle glaucoma utilizes unique mechanisms of action not previously available with existing drug choices. This activity will provide education on the efficacy, safety, and mechanism of action of these two new drugs and how they compare to traditional glaucoma treatments. |
Expiration |
Aug 16, 2023 |
Discipline(s) |
Optometry / Ophthalmology CE |
Format |
Journal |
Credits / Hours |
1 |
Accreditation |
ACCME, COPE |
Presenters / Authors / Faculty |
JACOB W. BRUBAKER, MD; IAN BENJAMIN GADDIE, OD; GAGAN SAWHNEY, MD; AND OLUWATOSIN U. SMITH, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an unrestricted educational grant from Aerie Pharmaceuticals. |
Keywords / Search Terms |
Evolve Medical Education LLC Free CE CME |